Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785551 | 0.86 | ALDH1A1 (0.39) | PDE10ABRD4JAK2JAK1 | |
| SCHEMBL785928 | 0.81 | PDE10A (0.34) | PDE10ABRD4WDR5SMOPDK2 | |
| SCHEMBL784682 | 0.80 | BRD4 (0.34) | BRD4POLB | |
| SCHEMBL785107 | 0.79 | WDR5 (0.37) | PDE10AWDR5SMOPDK2POLB | |
| SCHEMBL784462 | 0.77 | WDR5 (0.35) | PDE10AWDR5SMOPDK2KLKB1 | |
| SCHEMBL784800 | 0.77 | WDR5 (0.40) | WDR5SMOPDK2KLKB1 | |
| SCHEMBL784592 | 0.77 | WDR5 (0.36) | PDE10AWDR5SMOKLKB1 | |
| SCHEMBL785366 | 0.76 | WDR5 (0.38) | PDE10AWDR5SMOKLKB1 | |
| SCHEMBL785902 | 0.76 | CTSS (0.36) | PDE10AWDR5SMOPDK2KLKB1 | |
| SCHEMBL785506 | 0.76 | TAF1 (0.38) | WDR5SMOKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | PDE10A 589/4885BRD4 238/4885WDR5 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.